Skip to main content

Table 1 Demographics

From: A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation

Parameter

Definition

Average N (%)

[range]

Gender

Female/Male

3/9 (25/75)

 

Age at inclusion (years)

Median

55

[32–68]

BMI (kg/m2)

Median

29

[25–35]

Etiologya

Hepatitis C

8 (67)

 

Hepatitis B

2 (17)

 

Alcohol

5 (42)

 

Comorbiditya

Hypertension

4 (33)

 

Diabetes

2 (17)

 

Pulmonary disease

1 (8)

 

No comorbidity

6 (50)

 

ECOG at inclusion

0

7 (58)

 

1

5 (42)

 

Child–Pugh score at inclusion

5

5 (42)

 

6

6 (50)

 

7

1 (8)

 

MELDb score at inclusion

 

9

[6–13]

AFP level at inclusion (mg/L)

Baseline median

22.5

[2.3–2790]

<  100

9 (75)

 

≥  100

3 (25)

 

Criteria at inclusion

Within Milan

11 (92)

 

Within USCF

12 (100)

 

Tumor number at inclusionc

1

7 (58)

 

2

1 (8)

 

3

4 (33)

 

Longest tumor diameter at baselined (cm)

mRECIST median

2.5

[1.5–4.4]

Total diameter at baselined (cm)

mRECIST median

2.6

[1.8–6.3]

Explant histology

 Longest diameter (cm)

Median

4.3

[0.8–6.5]

 Total diameter (cm)

Median

5.0

[1.3–12.2]

 Tumor number

1/2/3/> 3

5/3/1/3

 

 Vascular invasion

Macro/Micro/None/undef

1/7/3/1

 

 Differentiation grade (Edmonson)

2/3/4/undef

2/8/1/1

 

 Mixed type HCC

Cholangiocellular diff

1 (8)

 
  1. apatients could have more than one factor, bMELD score including Na, crefers to screening radiology, done patient could not be evaluated according to mRECIST (n = 11)